Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,243.00
Bid: 1,244.80
Ask: 1,245.80
Change: 18.80 (1.54%)
Spread: 1.00 (0.08%)
Open: 1,212.40
High: 1,247.00
Low: 1,210.80
Yest. Close: 1,224.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GSK biotech asthma drug wins UK approval after extra price cut

LONDON, Dec 1 (Reuters) - GlaxoSmithKline's new injectable asthma drug Nucala has been recommended for use in Britain's state-run health service in the most severe patients, after the drugmaker provided further analyses on its use and made an additional price cut. The National Institute for

1 Dec 16 00:01

Injections, implants tested as new weapons to prevent HIV

* GSK to start large trials testing protective injection * Under-skin implants seen as promising long-term option * New HIV cases still running at 1.9 million annually By Ben Hirschler LONDON, Nov 29 (Reuters) - Scientists are taking the battle to prevent HIV to the next l

29 Nov 16 14:17

GlaxoSmithKline seeks European approval for shingles vaccine

(ShareCast News) - GlaxoSmithKline announced the regulatory submission of a marketing authorisation application to the European Medicines Agency for approval of its candidate shingles vaccine, Shingrix. The phase III clinical trial of the vaccine - for the prevention of shingles in people over 50 an

25 Nov 16 14:21

BUZZ-AstraZeneca: boosted by Liberum upgrade as Healthcare rallies

** AstraZeneca +1%, second-top riser on FTSE 100 in volume ** Liberum upgrades to "buy" v "hold" - with stock down 8 pct YTD, trading around 5-mth lows, risk/reward going into a rich seam of catalysts is now strongly to the upside ** Four major immuno-oncology readouts in 2017 (incl.

25 Nov 16 09:55

GlaxoSmithKline starts Phase III studies of daprodustat for anaemia

(ShareCast News) - GlaxoSmithKline has started a phase III development programme to investigate daprodustat for anaemia associated with chronic kidney disease. The programme includes two studies evaluating the safety and efficacy of daprodustat compared to recombinant human erythropoietin. ASCEND-D

24 Nov 16 11:17

Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks

By Lewis Krauskopf NEW YORK, Nov 23 (Reuters) - Eli Lilly & Co's massive setback for its experimental Alzheimer's disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwa

23 Nov 16 20:30

GSK EGPA treatment meets endpoints in phase 3 study

(ShareCast News) - GlaxoSmithKline said on Wednesday that both co-primary endpoints and all secondary endpoints were met in a "pivotal" phase III study investigating the efficacy and safety of it smepolizumab treatment in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyan

23 Nov 16 07:24

INSIGHT-Currency drop hits Egypt's medicine supplies, angering public

* Pharma companies halting imports of drugs after currency float * Govt unwilling to ease price controls, deepening shortages * Companies say govt plan to subsidise key drugs insufficient * Black market springs up By Arwa Gaballa and Eric Knecht CAIRO, Nov 22 (Reuter

22 Nov 16 13:27

GlaxoSmithKline seeks U.S. approval for triple lung drug

LONDON, Nov 21 (Reuters) - GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light. Britain's biggest drugmaker is vying with competitors including A

21 Nov 16 08:00

GlaxoSmithKline files for triple COPD therapy 18 months early

(ShareCast News) - GlaxoSmithKline has filed a US regulatory submission for a new three-drug inhaler treatment for patients with chronic obstructive pulmonary diseases such as chronic bronchitis and emphysema. The filing was achieved around 18 months earlier than originally planned, with a regulator

21 Nov 16 07:18

Glaxo's ViiV starts phase III studies for HIV-1

(ShareCast News) - Specialist HIV company ViiV Healthcare, which is majority-owned by GlaxoSmithKline with Pfizer and Shionogi Limited as shareholders, has started two phase III studies to evaluate an investigational long-acting, injectable regimen of cabotegravir and rilpivirine for the treatment o

18 Nov 16 14:46

WHO says funds secured for Africa pilots of world's first malaria vaccine

By Kate Kelland LONDON, Nov 17 (Reuters) - Funding for phase one of pilot deployments of the world's first malaria vaccine in sub-Saharan Africa has been secured and immunisation campaigns will begin in 2018, the World Health Organization (WHO) said on Thursday. The vaccine, known as

17 Nov 16 18:23

Ex-sleuths sue GlaxoSmithKline over imprisonment in China

LONDON, Nov 16 (Reuters) - Two former corporate investigators have sued GlaxoSmithKline, alleging the drugmaker misled them and induced them to investigate an innocent person, resulting in their imprisonment. The complaint, filed with the U.S. District Court in Philadelphia and made public

16 Nov 16 16:31

Drugmakers improve access for poor, GSK ranked top

LONDON, Nov 14 (Reuters) - The world's top drugmakers have improved access to medicines in developing countries but still need to do more to make a wider range of products affordable, according to a report on Monday. The Access to Medicine Index, which ranks the 20 leading pharmaceutical co

14 Nov 16 00:01

UPDATE 1-Pfizer offers cut-price pneumonia shot for humanitarian crises

* Prevenar vaccine at lowest price for emergencies * Pfizer to donate proceeds to refugee support groups * Move follows similar by rival drugmaker GSK (Adds response from MSF, background on pressure) By Kate Kelland LONDON, Nov 11 (Reuters) - U.S. pharmaceuticals group P

11 Nov 16 19:08

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.